115 related articles for article (PubMed ID: 37651880)
1. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs.
Zheng XM; Chen YS; Ban YJ; Wang YJ; Dong YX; Lei L; Guo B; Wang JT; Tang L; Li HL; Zhang JQ
Eur J Med Chem; 2023 Nov; 260():115754. PubMed ID: 37651880
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.
Wu CF; Wang QC; Chen R; Zhou HL; Wu TT; Du Y; Zhang NN; Zhang HM; Fan ZY; Wang LL; Hu CJ; Sang ZP; Li HL; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2022 Feb; 229():114055. PubMed ID: 34971874
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxamide derivatives as PI3Kα inhibitors via virtual screening and docking-based structure optimization.
Gu D; Zhang M; Cai L; Wang C; Zhou YB; Li J; Sheng R
Bioorg Med Chem; 2023 May; 86():117288. PubMed ID: 37126967
[TBL] [Abstract][Full Text] [Related]
5. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors.
Liu C; Cao Y; Zuo Y; Zhang C; Ren S; Zhang X; Wang C; Zeng Y; Ling J; Liu Y; Chen Z; Cao X; Wu Z; Zhang C; Lu J
J Adv Res; 2024 Mar; ():. PubMed ID: 38471647
[TBL] [Abstract][Full Text] [Related]
6. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
7. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
8. Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors.
Fu S; Liu J; Li C; Wei J; Yue H; Yang A; Wang K; Wu Y; Hou Y; Zhao Y
Bioorg Chem; 2023 Nov; 140():106738. PubMed ID: 37562315
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
[TBL] [Abstract][Full Text] [Related]
10. Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
Zhang N; Yu Z; Yang X; Zhou Y; Tang Q; Hu P; Wang J; Zhang SL; Wang MW; He Y
Eur J Med Chem; 2018 Sep; 157():37-49. PubMed ID: 30071408
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K
Chen R; Wang Z; Sima L; Cheng H; Luo B; Wang J; Guo B; Mao S; Zhou Z; Peng J; Tang L; Liu X; Liao W
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2155638. PubMed ID: 36650905
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
14. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W
Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474
[TBL] [Abstract][Full Text] [Related]
16. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
[TBL] [Abstract][Full Text] [Related]
18. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
